Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca’s Real-World Outcomes Deal With IMS Aims To Turn Treatment Data Into Business Decisions

This article was originally published in The Pink Sheet Daily

Executive Summary

Accessing IMS Health’s European electronic health records and jointly building a customized data analysis platform will inform AstraZeneca’s R&D priorities and support outcomes claims of newly-launched drugs.

You may also be interested in...



Creating Value In Pharma-Health Plan Collaborations

A wave of research-based collaborations between pharmaceutical companies and payors is enabling a new level of credibility, trust, and joint efforts to enhance patient care.

Germany’s Pricing Revolution: Why The World Should Be Watching

Germany’s new early-benefit assessment system for all new drugs launched since Jan. 1, 2011, radically changes the status of Europe’s largest market. It was once a bastion of free (and thus relatively high) pricing, which firms used to signal their drugs’ value to other markets. Now, prices of new drugs will be negotiated between sponsors and the country’s association of statutory sick funds, on the basis of an added-benefit score determined by the G-BA, or Federal Joint Committee. Since those net prices will be made public, and many other countries reference German prices, there’s a real risk of a downward price spiral across Europe.

AZ, IMS To Build Disparate Data Sets Into Broader Outcomes Consensus

Individual deals with payers or information providers won’t provide pharma with the breadth of outcomes data they need to secure reimbursement for their drugs. A far broader stakeholder consensus is required.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS073245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel